It is possible that upregulation of TNF-α is also associated with resistance to the combination therapy in NSCLC with TP53-GOF mutations and that anti-TNF-α treatment might be beneficial for such resistant tumors. This evidence concerns the gene TP53 and non-small cell lung carcinoma.